Results 81 to 90 of about 10,710,575 (236)

Breast cancer

open access: yesMorecambe Bay Medical Journal, 1960
     
openaire   +2 more sources

Prescription Refill Gap of Endocrine Treatment from Electronic Medical Records as a Prognostic Factor in Breast Cancer Patients [PDF]

open access: yes, 2019
Purpose: Discontinuation of hormone therapy is known to lead to a poorer prognosis in breast cancer patients. We aimed to investigate the prescription gap as a prompt index of medication adherence by using prescription data extracted from patient ...
박유랑   +8 more
core   +1 more source

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

open access: yesNew England Journal of Medicine, 2012
Background Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)–targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1. The
S. Verma   +13 more
semanticscholar   +1 more source

Breast cancer

open access: yesJournal of the Royal College of Physicians of Edinburgh, 2010
Breast cancer is now the most common cancer of women in the UK and incidence is increasing. Because of major treatment advances and earlier diagnosis over the past 40 years, survival rates have been improving gradually and women diagnosed with breast cancer today are almost twice as likely to survive for 10 years or longer as women 40 years ago ...
openaire   +2 more sources

Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer [PDF]

open access: yes, 2010
Tamoxifen is the most widely prescribed anti-estrogen treatment for patients with estrogen receptor (ER)-positive breast cancer. However, there is still a need for biomarkers that reliably predict endocrine sensitivity in breast cancers and these may ...
Liang, Liang   +29 more
core   +2 more sources

Meeting Highlights: The Second Consensus Conference for Breast Cancer Treatment in Korea [PDF]

open access: yes, 2017
The Korean clinical practice guideline recently developed by the Korean Breast Cancer Society to address the national clinical situation is currently under revision ahead of a seventh recommendation.
정준   +4 more
core   +1 more source

Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers associated with treatment response of neoadjuvant therapy with TCbHP regimen in HER2 + breast cancer

open access: yesBreast Cancer Research
Background This study aimed to explore potential indicators associated with the neoadjuvant efficacy of TCbHP regimen (taxane, carboplatin, trastuzumab, and pertuzumab) in HER2 + breast cancer (BrCa) patients.
Ningning Zhang   +9 more
doaj   +1 more source

Breast Cancer Tissue Bank Sample and Image Collection

open access: yes
This is a collection of samples of breast cancer and normal breast, also including images of tissue samples, and blood samples. Samples and images are made available from the Breast Cancer Tissue Bank for research into breast cancer including its causes,

core  

Breast Cancer Tissue Bank Blood Samples

open access: yes
This BCTB subcollection consists of blood samples taken from breast cancer patients and others. It is further broken down into a number of blood components.

core  

Neoadjuvant anti-HER2 antibody-drug conjugate SHR-A1811 in Hormone Receptor-positive, HER2-low Breast Cancer: A Phase 2 Clinical Trial (HELEN-015)

open access: yesNature Communications
As an anti-HER2 antibody-drug conjugate, SHR-A1811 has exhibited significant antitumor activity in patients with HER2-low advanced breast cancer. This trial aims to explore the efficacy and safety profile of SHR-A1811 as a neoadjuvant therapy for hormone
Dechuang Jiao   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy